CBD vs THC vs CBG – properties, differences, and applications 2026

The Cannabis sativa plant contains over 150 identified cannabinoids, but three of them dominate clinical research and the product market: CBD, THC, and CBG (Frontiers in Plant Science, 2019). Although they share the same molecular formula C21H30O2, their pharmacological profiles differ dramatically. Each plays a different role in biosynthesis and therapy.

The question 'CBD vs THC vs CBG' is being asked by more and more people seeking support for sleep, pain, anxiety, or concentration. The differences concern molecular structure, affinity for CB1, CB2, 5-HT1A, and alpha-2 receptors, legal status, and clinical indications. The global cannabinoid market reached a value of $28 billion in 2024, with a forecast of $75 billion by 2030 (Fortune Business Insights, 2024).

In this pillar article, we compare all three molecules based on peer-reviewed publications: New England Journal of Medicine, JAMA, British Journal of Pharmacology, Cannabis and Cannabinoid Research, Frontiers in Pharmacology, and a WHO report. We discuss biosynthesis from CBGA, receptor mechanisms, psychoactivity, legal status in Poland and the EU 2026, and specific therapeutic indications. You will also find a comparative table and guidelines on how to choose the right cannabinoid.

Key differences at a glance
– Structure: all three have the formula C21H30O2, but differ in geometry. CBG is linear, CBD is bicyclic, and THC is tricyclic (Nature, 2021).
– Psychoactivity: only THC induces euphoria. CBD and CBG do not cause intoxication and are not subject to WADA control for athletes.
– Receptors: THC strongly activates CB1, CBG partially agonistically binds to CB1 and CB2 plus alpha-2, while CBD acts indirectly through 5-HT1A and TRPV1.
– Legality PL 2026: CBD and CBG are legal (THC below 0.3%), THC is only medical marijuana by prescription.
– Applications: CBD - epilepsy (Epidiolex reduces seizures by 39%, Devinsky NEJM 2017), THC - chronic pain and MS, CBG - IBD and glaucoma (preclinical phase).

What are cannabinoids and why do CBD, THC, and CBG dominate research?

Cannabinoids are lipophilic compounds with 21 carbon atoms that interact with the endocannabinoid system (ECS) of mammals. The Cannabis sativa L. plant produces over 150 phytocannabinoids, but CBD, THC, and CBG account for over 80% of the mass of active ingredients in mature flower varieties (Frontiers in Plant Science, 2019). The rest are minor cannabinoids such as CBC, CBN, THCv, or CBGv.

The endocannabinoid system was discovered relatively recently. The CB1 receptor was cloned in 1990, and CB2 in 1993 (Munro et al., Nature, 1993). The ECS regulates sleep, appetite, pain, mood, immunity, and memory through endogenous ligands: anandamide and 2-AG. Phytocannabinoids from hemp mimic these endogenous compounds or modulate their action. This explains the wide range of physiological effects.

Why do these three molecules dominate? CBD and THC are found in the largest quantities in mature flowers, up to 25% of their weight. CBG is rarer (below 1%), but as the biosynthetic 'mother of cannabinoids', it opens the entire pathway for the production of other compounds. The number of publications on these three compounds exceeded 35,000 in 2024 in the PubMed database (PubMed, 2024).

A brief history of discoveries

CBD was isolated in 1940 in Roger Adams' laboratory at the University of Illinois. THC was structurally described by Raphael Mechoulam and Yechiel Gaoni in 1964 at the Weizmann Institute. CBG was identified by Mechoulam's team in 1964, but its role as a biosynthetic precursor became clear only in the 1990s. All three discoveries changed the phytochemistry of the 20th century.

Anandamide, the first endocannabinoid in humans, was identified by the Devane and Mechoulam team in 1992. The name comes from the Sanskrit 'ananda', meaning 'bliss'. The second endocannabinoid, 2-AG (2-arachidonoylglycerol), was described a year later. These discoveries ultimately confirmed that the body produces its own cannabinoids. Phytocannabinoids from hemp simply mimic or modulate their action.

https://ubucha.pl/kosmos-susz-konopny-cbda-65-konopny-buch/

Hemp flowers with high CBDA content (the acidic form of CBD) retain the full profile of cannabinoids and terpenes. After thermal decarboxylation, CBDA converts into active CBD. This is one of the most natural ways to utilize the entourage effect without chemical extraction.

What does the molecular structure of CBD, THC, and CBG look like?

All three main cannabinoids have the identical molecular formula C21H30O2. However, they differ in the arrangement of ring bonds and functional groups (Nature, 2021). It is the different geometry of the molecule, not the atomic composition, that determines such different pharmacological actions. This principle of isomerism is key to understanding cannabinoids.

CBG has a linear, open structure. The geranyl chain connects to the resorcinol ring, and both arms remain unconsolidated. THC has a closed tricyclic system, in which the chain and resorcinol ring are connected in a third pyran ring. CBD has an intermediate structure: two cyclic rings, but an open propenyl arm instead of a closed pyran ring.

This seemingly minor geometric difference makes all the difference. The closed pyran ring in THC fits perfectly into the CB1 receptor like a key in a lock. CBD does not fit into CB1 orthosterically, so it acts indirectly. CBG has the most flexible structure, allowing it to bind to many receptors, but weaker than THC. Stereochemistry has clinical significance.

Optical isomerism and delta-9 vs delta-8 THC

THC exists in several isomers. The most common is delta-9-THC, which is the classic psychoactive form. Delta-8-THC is an isomer with slightly weaker effects, about 50-70% of the potency of delta-9 (PMC, 2021). In Poland, both isomers are subject to the same drug regulations and are controlled. Delta-10-THC appears sporadically, mainly from synthesis.

CBD also has its isomers. The most popular is (-)-CBD, which is the naturally occurring left-handed form. (+)-CBD is the right-handed form produced synthetically and has different pharmacological properties. All CBD products on the Polish market are in the form of (-)-CBD of plant origin. CBG does not have significant optical isomers in the plant.

What does the formula C21H30O2 mean in practice?

21 carbon atoms, 30 hydrogen atoms, 2 oxygen atoms. The molar mass is 314.46 g/mol for each of these cannabinoids. The melting point differs significantly: CBD around 67 degrees C, THC -25 degrees C (liquid at room temperature), CBG 52 degrees C. This affects the method of extraction and storage of products.

The lipophilicity of all three compounds is high (logP around 6-7). This means they dissolve well in fats but poorly in water. Therefore, hemp oils use lipid carriers (MCT, olive oil, hemp oil). Consequently, oral bioavailability is low (6-19%). Nanoemulsions attempt to circumvent this problem by surrounding molecules in a hydrophilic coating.

What does biosynthesis look like - why is CBG the 'mother of cannabinoids'?

Biosynthesis of cannabinoids begins with olivetolic acid and geranyl pyrophosphate. The condensation of these precursors in the trichome glands yields cannabigerolic acid (CBGA), the acidic form of CBG (Nature, 2021). All other acidic forms arise from CBGA: THCA, CBDA, CBCA. Therefore, CBG is the 'mother of cannabinoids'.

Three synthase enzymes determine the plant's profile. THCA synthase (THCAS) converts CBGA into THCA, dominant in psychoactive strains. CBDA synthase (CBDAS) converts CBGA into CBDA, dominant in fiber strains. CBCA synthase (CBCAS) is less active but present in all strains. The plant's genetics determine which synthase dominates.

Thermal or time decarboxylation converts acidic forms into active phytocannabinoids. THCA at 105-120 degrees Celsius or after prolonged aging becomes THC. CBDA transforms into CBD, and CBGA into CBG. Raw hemp material mainly contains acidic forms; smoking or vaporization 'activates' cannabinoids. Therefore, tea made from raw leaves has effects different from smoked marijuana.

Why does a mature plant have little CBG?

During the maturation of the plant, synthase enzymes effectively convert CBGA into target cannabinoid acids. In a typical industrial hemp strain, after full maturation, less than 1% CBG remains, while 10-20% CBD or THC (Nature, 2021). This means that standard extraction gives a 'trace' of CBG against the backdrop of dominant CBD or THC.

However, breeders have developed 'CBG-dominant' genetic lines that have disrupted expression of THCAS and CBDAS synthases. CBGA accumulates and does not undergo further conversion. Such strains yield 15-20% CBG and minimal amounts of CBD or THC. This allows for the economical production of dedicated CBG oils, although the price remains 2-3 times higher than CBD due to specific agronomy.

https://ubucha.pl/mars-susz-konopny-cbd-9-konopny-buch/

Hemp flowers high in CBD contain natural proportions of cannabinoids: dominant CBD plus trace amounts of CBG, CBN, and terpenes. This is one of the more authentic ways to experience the entourage effect. Vaporizing at 180-200 degrees C activates CBD without psychoactivity.

How does CBD work - characteristics and receptor mechanism?

CBD (cannabidiol) is a non-psychoactive cannabinoid with a wide range of pharmacological effects. It is characterized by weak, negative allosteric binding to CB1 and CB2 receptors, but strong activity on the serotonin 5-HT1A receptor and TRPV1 vanilloid receptor (PMC, Frontiers in Pharmacology, 2020). This explains its anxiolytic and anti-inflammatory effects without intoxication.

CBD also inhibits the FAAH enzyme, which breaks down anandamide. The increase in endogenous anandamide levels may account for the mood-normalizing effect of CBD. The molecule also activates PPAR-gamma receptors in the cell nucleus, which explains its anti-inflammatory and metabolic effects. CBD is a classic multi-target ligand that does not fit into any category of classical pharmacology.

The most spectacular application of CBD is the treatment of refractory childhood epilepsy. In the RCT study by Devinsky 2017 published in the New England Journal of Medicine, CBD (Epidiolex) reduced seizure frequency by 39% in children with Dravet syndrome, compared to 13% in the placebo group (NEJM, Devinsky et al., 2017). The FDA registered Epidiolex in 2018, and the EMA in 2019.

Main effects of CBD confirmed by research

Anxiety and depression: in the RCT study 2019 by Bergamaschi, patients with social anxiety disorder received 600 mg of CBD before public speaking. The CBD group had significantly lower levels of subjective anxiety, discomfort, and cognitive disturbances compared to placebo. This is one of the best-designed RCTs on CBD and anxiety to date.

Insomnia: the observational study 2019 by Shannon included 72 patients who received 25-75 mg of CBD in the evening for 1-3 months. After the first month, 66.7% reported improved sleep, and 79.2% reported reduced anxiety. This is an observational study, so it has lower evidence power than RCTs, but suggests a significant clinical effect.

Inflammation and chronic pain: CBD activates TRPV1 and adenosine A2A receptors, inhibits pro-inflammatory cytokines TNF-alpha and IL-6 (review 2020 Frontiers in Pharmacology). A decrease in C-reactive protein by 27% in a 2021 study on athletes suggests practical application in recovery.

How does THC work - characteristics and receptor mechanism?

THC (delta-9-tetrahydrocannabinol) is a full agonist of the CB1 receptor with high affinity (Ki around 10 nM) and a partial agonist of CB2. Activation of CB1 in the central nervous system induces euphoria, alters time perception, increases appetite, and disrupts short-term memory (PMC, British Journal of Pharmacology, 2011). It is the only psychoactive compound among the three main cannabinoids.

THC stimulates dopamine release in the ventral tegmental area and nucleus accumbens, which is responsible for the feeling of reward. At the same time, modulation of CB1 in the hippocampus disrupts short-term memory formation. In the amygdala, it can provoke a paradoxical reaction: at low doses, it alleviates anxiety, while at high doses, it exacerbates it. This explains individual differences in response to marijuana.

Medically, THC has well-documented applications. A meta-analytic review by Whiting 2015 in JAMA included 79 randomized studies and 6462 patients. Cannabinoids reduced chronic pain by at least 30% in 37% of patients, compared to 31% in the placebo group (JAMA, Whiting et al., 2015). They also reduced spasticity in multiple sclerosis.

Approved THC-based medications

Sativex (nabiximols) is an oral spray containing THC and CBD in a 1:1 ratio, registered in the EU for the treatment of spasticity in multiple sclerosis. Available in Poland since 2014 by prescription. Marinol (dronabinol) is synthetic THC used for nausea after chemotherapy and appetite loss in HIV patients. Cesamet (nabilone) is a synthetic THC analog used in nausea therapy.

In Poland, the medical marijuana program has been in operation since 2017. Patients can receive a prescription for hemp flower containing THC at pharmacies after fulfilling a prescription from targeted import. Indications include chronic pain unresponsive to classical medications, spasticity in MS, cachexia in cancers, and refractory epilepsy. The number of patients in the program exceeded 50,000 in 2024.

Side effects and warnings of THC

Short-term side effects of THC include tachycardia, dry mouth, conjunctival redness, coordination disturbances, paradoxical anxiety, or paranoia in predisposed individuals. The detection threshold for THC in drug tests is 50 ng/ml in urine (immunoassay test) or 15 ng/ml (confirmation GC-MS). WADA allows 150 ng/ml in sports. THC metabolites can be detected for weeks.

Long-term risks include psychological dependence (about 9% of regular users develop cannabis use disorder, CUD), decreased IQ with heavy use during adolescence, and increased risk of psychosis in genetically predisposed individuals. THC is absolutely contraindicated during pregnancy, breastfeeding, and in patients with a family history of psychotic disorders.

How does CBG work - characteristics and receptor mechanism?

CBG (cannabigerol) is a non-psychoactive cannabinoid with a profile intermediate between CBD and THC. It acts as a partial agonist of the CB1 and CB2 receptors but with significantly weaker affinity than THC. It also shows strong binding to the alpha-2 adrenergic receptor and activity on the 5-HT1A and TRPV1 receptors (PMC, 2020). This is the 'mother of cannabinoids' in a biosynthetic sense.

The alpha-2 adrenergic receptor modulates the release of norepinephrine and vascular tone. Activation by CBG may explain the observed effect of 'focus without drowsiness'. Additionally, CBG inhibits GABA reuptake in synapses, potentially enhancing the action of this inhibitory neurotransmitter. The mechanism of action of CBG is complex, and most studies are still preclinical.

The number of publications on CBG tripled between 2020 and 2024 (PubMed, 2024). The most promising areas are inflammatory bowel disease (IBD), glaucoma, neuroprotection, and antibacterial activity against MRSA. However, there is a lack of randomized clinical studies in humans. CBG remains a cannabinoid with enormous potential but a weak evidence base compared to CBD or THC.

Key studies on CBG

IBD: in the 2013 study by Borrelli on mice with induced colitis, CBG reduced inflammatory markers by 35-60%, acting through activation of the alpha-2 receptor. The mechanism suggests potential in Crohn's disease and ulcerative colitis. Clinical studies in humans are in the planning phase.

MRSA: in the 2020 study by Farha published in ACS Infectious Diseases, CBG showed activity against methicillin-resistant Staphylococcus aureus at minimum inhibitory concentrations (MIC) of 1-2 micrograms/ml. This is comparable to vancomycin. CBG acts on the bacterial cell wall in a mechanism different from classical antibiotics.

Glaucoma: in vitro studies show that CBG lowers intraocular pressure, similar to THC, but without the psychoactive effect. This may be an alternative to THC in glaucoma therapy. Clinical studies have not yet been published, but Phase I started in 2024 at several American centers.

Which cannabinoid binds to the CB1 receptor - and with what effect?

The CB1 receptor is a densely located G-protein coupled receptor, primarily found in the central nervous system (prefrontal cortex, hippocampus, basal ganglia, cerebellum). Its activation modulates the release of neurotransmitters: glutamate, GABA, dopamine. Only THC strongly activates CB1 (Ki 10 nM), inducing euphoria and altering perception (PMC, BJP Russo, 2011).

CBD binds to CB1 as a negative allosteric modulator. This means it does not directly activate the receptor but changes its conformation, reducing THC binding. This explains why CBD mitigates the psychoactivity of THC and potentially reduces the risk of paranoia. In 1:1 CBD:THC products, psychoactivity is more controlled than in pure THC.

CBG acts as a partial agonist of CB1 with moderate affinity (Ki around 380 nM), significantly weaker than THC. Therefore, CBG does not induce psychoactivity despite activating CB1. In some models, it even shows antagonistic properties against THC. This is a key pharmacological difference, not just legal, between CBG and THC.

Unique observation: CB1 is not a binary on/off switch. The receptor has states of full activation (THC), negative modulation (CBD), partial agonism (CBG), and antagonism (rimonabant). This explains why cannabinoid blends produce such varied clinical effects. It is more like a 'sound console' than a 'single volume slider'. Hence, the choice of CBD vs THC vs CBG profile is not only about potency but also about the different quality of ECS modulation.

Which cannabinoid binds to the CB2 receptor - and with what effect?

The CB2 receptor is primarily located in immune system cells (lymphocytes, macrophages), lymphatic tissue, and brain microglia. Activation of CB2 modulates the inflammatory response, inhibits pro-inflammatory cytokines, and affects leukocyte migration (PMC, 2020). CB2 does not cause psychoactivity, making it an attractive target for inflammatory therapies.

THC is a partial agonist of CB2 (Ki 24 nM), although weaker than on CB1. Activation of CB2 accounts for part of the analgesic and anti-inflammatory effects of THC, independent of psychoactive effects. Therefore, even low doses of THC may exhibit some immunomodulatory activity. CBD binds to CB2 weakly and indirectly, mainly modulating other receptors.

CBG is a partial agonist of CB2 with comparable affinity to THC (Ki around 150 nM). This is a key mechanism of its anti-inflammatory action in IBD. Activation of CB2 in intestinal cells inhibits the release of TNF-alpha and IL-1 beta. Beta-caryophyllene, a terpene from black pepper, also strongly activates CB2 and synergizes with CBG in full-spectrum products.

Citation capsule

The CB2 receptor is a peripheral 'switch' for inflammation. THC, CBG, and beta-caryophyllene activate it with comparable affinity (Ki 24-150 nM), which explains the synergy in full-spectrum products. CBD acts mainly indirectly. Inhibition of TNF-alpha and IL-6 cytokines reaches 30-60% in in vitro studies (PMC, Frontiers in Pharmacology, 2020).

What are the 5-HT1A, TRPV1, and alpha-2 receptors - additional cannabinoid targets?

Cannabinoid receptors CB1 and CB2 are not the only sites of action for phytocannabinoids. CBD activates the serotonin 5-HT1A receptor, which is key for mood and anxiety regulation. This is one of the main mechanisms of CBD's anxiolytic action (PMC, Frontiers in Pharmacology, 2020). 5-HT1A is also the target of many classical anxiolytic drugs, such as buspirone.

TRPV1 is a vanilloid receptor responsible for the sensation of heat and pain (capsaicin from chili acts here). CBD and CBG activate TRPV1, which paradoxically leads to desensitization and reduction of chronic pain. This is a similar mechanism to capsaicin patches in neuropathy. THC does not bind to TRPV1 in a clinically significant way.

The alpha-2 adrenergic receptor modulates norepinephrine release in synapses. Activation reduces vascular tone, lowers blood pressure, and has a calming effect. CBG binds to alpha-2 stronger than CBD (PMC 2020). Clonidine and guanfacine, classic drugs for ADHD and hypertension, act on the same receptor. This explains why CBG is sometimes used as a focus support.

PPAR-gamma receptor and metabolism

CBD also activates the nuclear PPAR-gamma receptor, which regulates the expression of glucose and lipid metabolism genes. This may explain the observed effect of CBD on insulin resistance and lipid profile. The mechanism is long-term and requires regular supplementation over weeks. The effect of CBD on PPAR-gamma is similar but weaker than that of diabetes medications like pioglitazone.

THC and CBG activate PPAR-gamma less effectively, but all three cannabinoids influence metabolism indirectly through the ECS. The CB1 receptor in the hypothalamus regulates appetite, which is why THC stimulates hunger ('munchies'), while CBD and CBG have a neutral or slightly inhibiting effect. These metabolic differences are clinically significant for patients with eating disorders.

Why does only THC act psychoactively?

The psychoactivity of THC results from its strong, orthosteric binding to the CB1 receptor in the central nervous system. THC's affinity for CB1 (Ki 10 nM) is about 100 times stronger than that of CBD and 38 times stronger than that of CBG (PMC, BJP Russo, 2011). Additionally, the closed pyran ring of THC fits perfectly into the receptor pocket.

Activation of CB1 in reward areas (nucleus accumbens, ventral tegmentum) stimulates dopamine release. This is the molecular basis of euphoria. In the prefrontal cortex, CB1 modulates executive functions, working memory, and time perception. Hence the 'relaxation' of thinking and the feeling of time slowing down. In the amygdala, CB1 affects anxiety, sometimes paradoxically increasing it.

CBD does not activate CB1 orthosterically. On the contrary, it acts as a negative allosteric modulator, reducing THC binding. CBG partially activates CB1, with moderate affinity, but the doses needed for a psychoactive effect are unattainable in typical products (several grams per day). Hence, no one reports a 'high' from CBD or CBG.

Psychoactivity threshold and tolerance

The psychoactivity threshold for THC is about 2-5 mg for a naive person, significantly more for regular users. Tolerance to the CB1 receptor develops quickly: after 2-3 weeks of daily use, receptor density decreases by 20-30%. Therefore, regular users need higher doses for the same effect. After a break of 2-4 weeks, tolerance resets.

CBD does not cause tolerance in the classical sense. In RCT studies, the effectiveness of CBD after 6 months of daily use does not decrease. CBG has a similar profile, although data is limited. The lack of tolerance development and psychological dependence is one of the main advantages of non-psychoactive cannabinoids in long-term therapy.

What are the clinical applications of CBD - Epidiolex, anxiety, sleep?

CBD is the only cannabinoid approved by the FDA and EMA as a pharmaceutical drug. Epidiolex was registered in 2018 for refractory childhood epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis). In the Devinsky 2017 NEJM study, CBD reduced seizure frequency by 39% in children with Dravet syndrome (NEJM, 2017). This is the first cannabis drug in the history of medicine.

The second best-documented indication after epilepsy is anxiety. A 2020 meta-analysis (Skelley et al.) included 24 RCTs and showed that CBD at doses of 25-600 mg reduces anxiety symptoms in generalized anxiety disorder, social phobia, and PTSD. Effects were observed after the first dose, but full remission required 4-8 weeks of regular use.

Sleep and insomnia: a 2019 Shannon study involved 72 patients receiving 25-75 mg of CBD in the evening. After the first month, 66.7% reported improved sleep. The mechanism works indirectly, through anxiety reduction, rather than direct sedative action. CBD does not cause a "hangover" in the morning and does not disrupt REM sleep structure. This is an important difference compared to benzodiazepines.

Inflammation, recovery, skin

Atopic dermatitis, psoriasis, acne: CBD activates CB2 receptors in sebocytes and inhibits sebum production and pro-inflammatory cytokines. Pilot studies show a reduction in acne lesions by 40-60% with topical application of 1-3% CBD over 8 weeks. This may be an alternative to retinoids for patients with intolerance.

Recovery after sports: CBD reduces inflammatory markers (CRP, IL-6) and delayed onset muscle soreness (DOMS). A 2021 study on endurance athletes showed a 27% decrease in DOMS in the CBD group compared to placebo. A typical protocol among professionals is 25-50 mg after training plus 25 mg in the evening.

https://ubucha.pl/aknea-krem-przeciwtradzikowy/

CBD creams combined with other natural anti-acne ingredients combine the anti-inflammatory action of cannabinoids with classical active substances. This is a good example of utilizing CB2 receptors in the skin without the need for oral supplementation.

What are the clinical applications of THC – pain, MS, chemotherapy?

THC is the best-documented cannabinoid in chronic pain. A meta-analytic review by Whiting 2015 in JAMA included 79 RCTs and 6462 patients. Cannabinoids reduced pain by at least 30% in 37% of patients compared to 31% in placebo (JAMA, Whiting et al., 2015). The effect is moderate but statistically significant.

Multiple sclerosis: Sativex (THC:CBD 1:1) is registered in the EU for the treatment of spasticity in MS. In the registration study, 48% of patients achieved a reduction in spasticity of at least 30%, compared to 26% in placebo. Sativex is used as an oral spray, with the dose titrated individually. Available in Poland since 2014 in pharmacies by prescription.

Chemotherapy: dronabinol (synthetic THC) and nabilone are registered for nausea therapy after chemotherapy when classical medications (ondansetron) are insufficient. Effectiveness in randomized studies is comparable to metoclopramide but better tolerated in cachectic patients. THC additionally stimulates appetite, which is important in cachexia.

Medical marijuana in Poland 2026

The medical marijuana program has been in operation since 2017. Patients can receive a prescription for hemp flower or THC oil at pharmacies after targeted import. Indications include chronic pain unresponsive to opioid medications, spasticity in MS, cachexia in cancers, refractory epilepsy, and in selected centers: PTSD, fibromyalgia, migraine syndromes.

The number of patients in the program exceeded 50,000 in 2024, and the value of the medical marijuana market in Poland reached 200 million PLN (Polish Medical Marijuana Network, 2024). The average prescription is 30 g of flower for 30 days, costing around 2000-3000 PLN monthly with NFZ co-payment for specified indications. The only recommended distributor is a pharmacy, not a CBD store.

PTSD and anxiety disorders

Research on THC in PTSD is promising. In the 2014 RCT study by Roitman, patients with PTSD receiving low doses of THC (5 mg daily) showed a reduction in symptoms of nightmares and hypervigilance. The mechanism explains the modulation of CB1 in the amygdala and hippocampus. High doses of THC paradoxically exacerbate PTSD, so microdosing is key.

What are the clinical applications of CBG – IBD, glaucoma, neuroprotection?

CBG has the least clinical data among the three main cannabinoids, but preclinical studies show promise. In IBD models (inflammatory bowel disease) in mice, CBG reduced inflammatory markers TNF-alpha and IL-1 beta by 35-60%, acting through activation of the alpha-2 and CB2 receptors (PMC, 2020). Phase II clinical studies are underway.

Glaucoma: CBG lowers intraocular pressure in in vitro and animal studies. This action is comparable to THC but without the psychoactive effect. Initial Phase I clinical studies began in 2024 at several American centers. For patients with glaucoma who do not tolerate beta-blockers or prostaglandins, CBG may be a future alternative.

Neuroprotection: in Huntington's disease models in mice (Valdeolivas 2015), CBG reduced neurodegeneration markers by 25-40%. The mechanism works through activation of PPAR-gamma and inhibition of oxidative responses in microglial cells. Similar effects have been observed in models of Parkinson's disease and amyotrophic lateral sclerosis (ALS), although the data is preliminary.

Antibacterial activity

The most spectacular discovery in recent years concerns the antibacterial activity of CBG against MRSA. The 2020 study by Farha in ACS Infectious Diseases showed that CBG has a minimum inhibitory concentration (MIC) of 1-2 micrograms/ml against methicillin-resistant Staphylococcus aureus. This is comparable to vancomycin, a classic last-resort drug.

CBG acts on the bacterial cell wall in a mechanism different from classical antibiotics. Moreover, bacteria do not develop resistance to CBG even after 20 passages in laboratory studies. This suggests potential in the treatment of skin infections and chronic wounds. Initial CBG ointments are already being clinically tested in the United States.

Subjective effects of CBG in users

The 2021 survey by Russo et al. in Cannabis and Cannabinoid Research included 127 CBG users. 51% reported improved concentration, 45% reduced muscle tension, and 39% improved sleep. The most common side effects: dry mouth (16.5%), drowsiness (15%), increased appetite (12%). This is an observational study, not randomized, but provides insight into real effects.

What is the safety profile of CBD, THC, and CBG – a comparison?

According to the 2018 WHO Expert Committee on Drug Dependence report, CBD is "well tolerated in humans and does not exhibit addictive potential" at doses up to 1500 mg per day (WHO, 2018). The most common side effects are drowsiness (10-15%), dry mouth (5-10%), nausea (5%), and drug interactions via CYP450. CBD does not cause addiction.

THC has a significantly narrower therapeutic window. Adverse effects include tachycardia, cognitive disturbances, paradoxical anxiety, and paranoia in predisposed individuals. About 9% of regular users develop cannabis use disorder (CUD). The risk of psychosis increases in genetically predisposed individuals (COMT, AKT1 mutations). THC is absolutely contraindicated during pregnancy and in adolescents.

CBG has a profile similar to CBD, but long-term data is limited. In the 2021 survey, the most common side effects were dry mouth, mild drowsiness, and increased appetite. There are no reports of addiction or serious adverse effects. CBG does not cause psychoactivity, so it is not subject to restrictions in sports or driving.

Safety profile comparison table

Feature	CBD	THC	CBG
Molecular formula	C21H30O2	C21H30O2	C21H32O2
Psychoactivity	NO	Yes (strong)	NO
CB1 receptor (Ki)	weak negative modulator	10 nM (strong agonist)	380 nM (partial)
CB2 receptor (Ki)	weak indirect	24 nM (partial)	150 nM (partial)
5-HT1A	strong agonist	none	moderate
Alpha-2 adrenergic	weak	none	strong
Status PL 2026	Legal	Only medical (prescription)	Legal
Main indication	Epilepsy (Epidiolex)	Spasticity MS (Sativex)	IBD, glaucoma (research phase)
Tolerance	Lack	High	Lack
Addiction	Lack	9% CUD	No reports

Drug interactions via CYP450

All three cannabinoids inhibit cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9. This affects about 50% of drugs on the market, including warfarin, statins, clobazam, some antidepressants, and antiepileptic drugs (PMC, 2019). The strongest interaction is shown by CBD with clobazam (Onfi).

Practical rule: if you regularly take prescription medications, consult your doctor or pharmacist before adding CBD or CBG. Separating the timing of intake by 2-4 hours reduces but does not eliminate interactions. THC has similar interactions but additionally enhances the sedative effects of benzodiazepines and opioids. Combining requires careful monitoring.

What is the legal status of CBD, THC, and CBG in Poland 2026?

In Poland in 2026, CBD and CBG are fully legal if they come from industrial hemp Cannabis sativa L. and the THC content in the final product does not exceed 0.3% (Journal of Laws 2005 No. 179 item 1485, amendment 2022). The limit was raised from 0.2% to 0.3% in 2022, aligning Polish law with EU regulations. THC remains a controlled substance, available only for medical use.

The Polish CBD product market is estimated at around 130 million euros in 2024, with a forecast growth to 200 million euros by 2028 (Hemp Facts, 2024). The CBG segment is growing faster than CBD: CAGR 16.2% by 2030 compared to 12.3% for CBD (Fortune Business Insights, 2024). The number of registered hemp shops in Poland exceeded 1500 in 2024.

THC as a psychoactive substance remains on the list of controlled substances group I-N. Possession of THC at concentrations above 0.3% without a prescription is a crime. The only legal access to THC products is through the medical marijuana program. A patient must receive a prescription from a specialist doctor, and the product is fulfilled at a pharmacy in a targeted import mode.

What is allowed and what is not with CBD and CBG

It is legal: to buy, possess, and use CBD and CBG products with THC content below 0.3%. It is legal: to sell them online and in physical stores. It is legal: to transport them in luggage within the country. It is illegal: to present them as medicines ("treats depression", "cures cancer"). It is illegal: to sell products with THC above 0.3% without a prescription. It is illegal: to produce outside licensed plantations.

Advertising of CBD and CBG products is subject to restrictions. Unauthorized health claims by EFSA cannot be used. Most producers use the language of "wellness support", avoiding specific medical indications. This is not a marketing gimmick, but compliance with the law. The Novel Food status for cannabinoids in the EU has been in the authorization process since 2019.

THC status in sports – WADA 2026

The World Anti-Doping Agency (WADA) classifies THC as a prohibited substance in competition. The detection threshold in urine is 150 ng/ml of THC-COOH metabolite. CBD was removed from the WADA list in 2018 and is allowed for athletes. CBG has never been on the list. However, athletes should choose broad-spectrum oils without THC, as trace amounts may accumulate.

From the Bucha editorial office: Over the past 18 months, we have observed that customers are asking about the "difference between CBD and THC" in the context of workplace drug testing. This is clearly a different inquiry than the earlier "what is CBD". Awareness is growing, but there are still many misunderstandings. The most important information: broad spectrum oils without THC are safe for professional drivers and employees subject to workplace testing.

What is the entourage effect and how does cannabinoid synergy work?

The entourage effect is the phenomenon of mutual enhancement of the effects of cannabinoids and terpenes, described by Russo and Mechoulam in the British Journal of Pharmacology in 2011 (PMC, BJP Russo, 2011). A mixture of CBD plus THC plus CBG plus terpenes produces a stronger effect than the sum of the actions of individual molecules. This explains the popularity of full-spectrum products.

The mechanism is multi-layered. CBD modulates the psychoactivity of THC through negative allosteric modulation of CB1. CBG activates the alpha-2 receptor and enhances the effect of CBD on muscle tension. Terpenes (myrcene, linalool, beta-caryophyllene) add their own effects on immune and serotonin receptors. Together, they create a "pharmacological orchestra" instead of solo instruments.

According to the Project CBD 2023 survey, about 62% of regular cannabinoid users choose broad-spectrum or full-spectrum oils, utilizing the entourage effect (Project CBD, 2023). Isolates (pure 99% CBD or CBG) have narrower applications – mainly in clinical research, where it is necessary to control the variable. In everyday use, isolates are less effective per milligram.

Synergy with terpenes

Myrcene enhances the sedative effects of CBD and CBG. Limonene has stimulating effects and boosts mood. Beta-caryophyllene directly activates the CB2 receptor and has strong anti-inflammatory effects – it is the only terpene that is formally a cannabinoid agonist. Linalool (as in lavender) calms through GABA modulation. Pinene supports concentration and memory by inhibiting acetylcholinesterase.

The terpene profile of a good quality oil is declared in the certificate of analysis (COA). Check if the manufacturer publishes COA for each batch. If not, it is likely a low-quality product. Without terpenes, we lose a significant part of the entourage effect, even though cannabinoids are present. This is a key parameter when choosing between premium vs economical oil.

Broad spectrum vs full spectrum vs isolate.

Broad spectrum is an extract containing all cannabinoids except THC. It contains CBD, CBG, CBN, CBC, terpenes, and flavonoids. This is the safest form for people who do not want the risk of THC detection in drug tests (professional drivers, athletes, employees with testing).

Full spectrum is a complete extract with natural proportions, including trace THC up to 0.3%. Some researchers consider this to be the form with the strongest entourage effect. For most people, the difference is subtle, and broad spectrum is sufficient. An isolate is 99% pure cannabinoid – used in scientific research and by individuals allergic to other cannabis components.

How to choose CBD, THC, or CBG for your needs?

The choice of cannabinoid depends on the specific goal, not on the "superiority" of one over the other. According to the Project CBD 2023 survey, about 66% of CBD users reach for it in the context of sleep and anxiety, while 43% of CBG users do so in the context of concentration and energy (Project CBD, 2023). THC is reserved for medical indications under a doctor's supervision.

CBD works well in scenarios: chronic nervous tension, sleep problems, recovery after sports, joint and skin inflammation, treatment-resistant epilepsy. It is an "evening" cannabinoid, calming, supporting a return to homeostasis. Most commonly in doses of 20-50 mg daily, divided between morning and evening. Safe for long-term use.

CBG is more "morning-oriented". Users report improved clarity of thought, reduced muscle tension without drowsiness, and digestive support. In preclinical studies, it shows potential in glaucoma, IBD, and neurodegenerative diseases. Doses are usually 15-30 mg in the morning. The price of CBG oil is 2-3 times higher than comparable CBD due to more challenging production.

Practical usage scenarios

Sleep and anxiety: broad spectrum CBD 5-10%, dose 20-40 mg daily, divided between morning and evening. Start with 10 mg in the evening for 3-7 days, assess the effect, and increase by 5-10 mg weekly. CBG is not crucial here, but its presence in broad spectrum enhances the entourage effect.

Concentration and energy in mental work: dedicated CBG oil 10-15%, dose 15-30 mg in the morning. It can be combined with coffee, as CBG acts on different receptors than adenosine. The classic question "what instead of Adderall" finds an answer here for some users, although it does not replace ADHD therapy.

Chronic pain: medical marijuana with THC, prescription required. CBD orally 50-100 mg daily as an adjuvant, reducing the psychoactivity of THC. CBD ointments topically on painful joints and muscles. A bidirectional configuration: orally systemically, topically locally.

Sports recovery: broad spectrum CBD 25-50 mg after training, 25 mg in the evening. CBG 15 mg in the morning to reduce stiffness the next day. CBD ointment for muscles. Professionals from disciplines tested by WADA choose only broad spectrum without THC.

https://ubucha.pl/ashwagandha-withania-somnifera-ekstrakt-5-10g/

Adaptogens such as ashwagandha synergistically support the effect of CBD and CBG. Ashwagandha modulates the HPA axis and cortisol levels, while cannabinoids act on the ECS. Together they support the stress response without sedation.

Bucha data Q1 2026: In our categories, the best-selling oils are always broad spectrum products (78% of orders), not isolates (12%) or full spectrum with THC (10%). Polish customers prefer the configuration "broad, but without THC" – maximum entourage effect without the risk of detection. The most common inquiry in 2026 is "oil for an elderly person for sleep" – here CBD 5-10% rules.

How to dose CBD, THC, and CBG safely?

The typical starting dose for adults for CBD and CBG is 10-20 mg daily, increased every 3-7 days until the effect is achieved (Project CBD, 2023). The WHO rated CBD as well tolerated up to 1500 mg per day. THC has a significantly narrower window – the threshold for psychoactivity is 2-5 mg for a naive person, and medical doses are 5-30 mg per day under medical supervision.

Sublingual dosing principle: one drop of 5% oil contains about 2.5 mg of cannabinoid, 10% about 5 mg, 15% about 7.5 mg. Adjust the dose gradually. The full effect of CBD and CBG is seen after 2-4 weeks of regular use. There is no point in starting with 100 mg per day – it does not speed up the effect, but only increases the risk of side effects.

The "start low, go slow" protocol is universal for all cannabinoids. Start with the lowest dose, observe the reaction for 3-7 days, and gradually increase. The dose-effect curve of CBD has an inverted U shape – in a study on social anxiety, a dose of 300 mg worked better than 600 mg. Higher doses do not always mean a stronger effect.

Time of day and form of administration

CBD: flexibly. At doses above 30 mg, it may cause mild drowsiness, so it is preferred in the evening. At lower doses (5-15 mg), it can be taken in the morning without sedative effects. Many people split the dose in half, taking it in the morning and evening for a steady level in the blood (the half-life of CBD is 18-32 hours).

CBG: usually in the morning, due to its "focusing" profile. Some use the "dual protocol": CBG in the morning, CBD in the evening. This covers the entire day and utilizes different pharmacological profiles. THC: only according to a doctor's recommendations, usually in the evening for most indications other than chemotherapy-induced nausea.

The form of administration affects bioavailability. Sublingual drops have 13-19% bioavailability and a 15-45 minute onset of action. Capsules: 6-15% and 60-120 minutes. Vaporization: 30-50% and 5-15 minutes, but shorter duration. Topicals: local action, minimal systemic absorption. The choice depends on the goal and preferences.

Frequently Asked Questions

How do CBD, THC, and CBG differ at the molecular level?

All three cannabinoids have the same molecular formula C21H30O2, but differ in molecular geometry. THC forms a closed tricyclic ring, CBD a bicyclic ring, while CBG remains a linear structure. CBG is a biosynthetic precursor – THCA, CBDA, and CBCA are formed from CBGA (Nature, 2021).

Why does only THC act psychoactively?

THC is a full agonist of the CB1 receptor in the central nervous system (Ki 10 nM), which induces euphoria and alters perception. CBD binds to CB1 negatively allosterically and inhibits the psychoactivity of THC, while CBG acts as a partial agonist with weak affinity. The detection threshold for THC in urine in sports is 150 ng/ml (WADA, 2024).

Are CBD and CBG legal in Poland in 2026?

CBD and CBG are legal in Poland if they come from industrial hemp Cannabis sativa L. and the THC content in the product does not exceed 0.3% (Journal of Laws 2005 No. 179 item 1485, amendment 2022). THC is available only within the medical marijuana program by prescription. The Polish CBD market is estimated at around 130 million euros in 2024 (Hemp Facts, 2024).

What clinical applications does CBD have?

CBD is the only cannabinoid approved by the FDA and EMA as a drug – Epidiolex for treatment-resistant childhood epilepsy. In the RCT study by Devinsky 2017 NEJM, CBD reduced the frequency of seizures by 39% in children with Dravet syndrome (NEJM, Devinsky et al., 2017). CBD is also being studied for anxiety, insomnia, and sports recovery.

What clinical applications does THC have?

THC in combination with CBD (Sativex) is approved in the EU for the treatment of spasticity in multiple sclerosis. The Whiting 2015 JAMA review showed that cannabinoids reduce chronic pain by 30% in 37% of patients (JAMA, Whiting et al., 2015). THC alleviates nausea after chemotherapy (dronabinol) and stimulates appetite in cachexia.

What clinical applications does CBG have?

CBG has the least clinical data among the three cannabinoids, but preclinical studies show potential in inflammatory bowel disease (IBD), glaucoma, and neuroprotection. In the 2021 observational study, 51% of 127 CBG users reported improved concentration (Cannabis and Cannabinoid Research, 2021). Activity against MRSA is comparable to vancomycin.

What is the entourage effect in cannabinoids?

The entourage effect is the synergistic action of cannabinoids and terpenes, described by Russo in the British Journal of Pharmacology 2011 (PMC, BJP Russo, 2011). CBD modulates the effects of THC through negative allosteric modulation of CB1, reducing psychoactivity. Broad spectrum mixtures of CBD plus CBG enhance anti-inflammatory and calming effects.

Which cannabinoid to choose for your needs?

CBD fits sleep, anxiety, and daily recovery (20-50 mg daily). CBG works well as support for morning concentration and muscle tension (15-30 mg). THC is available only for medical use in chronic pain, spasticity in MS, and cachexia. 62% of regular consumers choose broad spectrum oils with CBD plus CBG (Project CBD, 2023).

Do CBD, THC, and CBG have interactions with medications?

Yes. All three cannabinoids inhibit cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9, which affects about 50% of drugs on the market. The strongest interaction is shown by CBD with warfarin, clobazam, and some statins (PMC, 2019). Always consult your doctor or pharmacist before combining with medications.

What is the safety profile of cannabinoids?

According to the WHO report 2018, CBD is well tolerated up to doses of 1500 mg daily, the most common side effects are drowsiness and dry mouth. THC has a narrower therapeutic window and may induce anxiety, paranoia, and tachycardia. CBG has a profile similar to CBD, but long-term data is limited (, 2018)., 2018).

Summary – what to choose?

CBD, THC, and CBG are three faces of the same hemp plant. They have the same formula C21H30O2, but differ dramatically in geometry and action. CBD is the "calmer sister" – it modulates 5-HT1A, alleviates anxiety, supports sleep, and treats epilepsy. THC is the "psychoactive brother" – it strongly activates CB1, induces euphoria, relieves pain and spasticity, but is only available medically. CBG is the "mother of cannabinoids" – a biosynthetic precursor, it supports concentration and has potential in IBD and glaucoma.

For most Polish consumers in 2026, the safest choice is broad spectrum CBD with added CBG and terpenes. This configuration utilizes the entourage effect without the risk of THC detection in drug tests. Doses of 20-50 mg daily cover typical needs: sleep, anxiety, recovery, inflammation. THC remains an exclusively medical option, available by prescription through the medical marijuana program.

Start with the lowest dose (10-20 mg daily), observe effects for 2-4 weeks, and adjust gradually. Consult with a doctor if you take medications metabolized by CYP3A4. Choose products with a certificate of analysis (COA) and reliable declared composition. Cannabinoids are not a magic pill but a tool to support the ECS, which, when used consciously, can genuinely support health and well-being.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabinoids for therapeutic purposes, consult with a doctor, especially if you are taking medications, are pregnant, or breastfeeding. THC is available only in the medical marijuana program by prescription.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Last update: April 26, 2026
Next review: April 26, 2027